The FDA rejected Novo Nordisk’s weekly insulin for treating diabetes in a rare setback for the company.

Biopharma layoffs have been higher over the past couple of years than during the industry’s boom times amid the pandemic; job cuts this year have mainly hit larger pharmaceutical companies.

In stark terms, the Federal Trade Commission released a report describing pharmacy benefit managers as wielding “enormous power.”

Continued growth and investor interest in creating novel neurotherapeutics hinge on their ability to adapt, pivot quickly, and embrace new approaches and development models.

AbbVie paid health care providers roughly $145.7 million last year to promote its drugs, the most a company has spent since such data became available.

A study reported for the first time a potential link between Novo Nordisk's GLP-1 drugs and an eye condition that can cause vision loss.

GSK reached a licensing agreement with mRNA-vaccine developer CureVac worth up to $1.8 billion to develop its vaccines for seasonal flu, Covid-19, and avian flu.

The unilateral decision by Peter Marks, a top FDA official, to approve a gene therapy for Duchenne muscular dystrophy looks even more surprising on a close examination.

The FTC is investigating Teva Pharmaceuticals after it refused to remove about two dozen patents for asthma and COPD inhalers from a federal registry.

Moderna will receive $176 million from HHS' BARDA to accelerate development of mRNA-based pandemic influenza vaccines, the company said Tuesday.

The owners of a drug wholesaler have been indicted for their alleged role in a conspiracy to distribute misbranded and diverted HIV pills.

An enormous experiment by Medicare shows a null effect: Financial incentives haven't gotten dialysis providers to move more patients to home dialysis or transplant. 

In today's Pharmalittle roundup, we're reading about the Purdue bankruptcy ruling, a Merck rejection, and more.

Psychedelic evangelists have been working to win over regulators since the 1980s, and those relationships helped persuade the FDA to sign off on research.

The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.

The FDA declined to approve an AbbVie therapy for patients with Parkinson's disease due to problems at a third-party manufacturer.

Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people.

A U.S. House panel is exploring a vote on two scaled-back health care bills to expand Medicare coverage of weight loss drugs and cancer screening tests.

BOSTON — Ginkgo Bioworks, the once-high-flying Boston life sciences firm, on Thursday said it has notified 158 employees that they will be laid off and expects to announce another batch of layoffs next week. On May 9, Ginkgo said it would slash labor

Parents accused of abuse are entitled to a fair trial. If the prosecution puts an expert witness on the stand, the defense should do the same. When physicians shy away…

After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:

For the third time in a month, Novo Nordisk has been affected by an office fire. A Novo Nordisk spokesman told a local newspaper “there is nothing to suggest that…

A pair of new studies suggest that combining two different kinds of inhibitors could be a new effective approach to immunotherapy.

In today's Pharmalittle roundup, we're reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more.

Is there a way to rewrite federal sterilization rules so they are better at protecting against coercion, while allowing people to get tubal ligations they want?

Freespira, which makes a digital treatment for panic and post-traumatic stress disorders, expects to break even by the end of 2025.

Increased awareness of H5N1 among clinicians is important for recognizing potential infections in humans and initiating public health investigations.

A 10-person startup called Marea has raised $190 million to help develop a drug to lower a type of cholesterol and a new way of attacking cardiovascular disease.

In today's Pharmalittle roundup, we're reading about an "unaffordable" Novartis drug, a new patent office rule, and more.